

18 February 2020

### March 2020 Pharmaceutical Schedule Dispatch

This dispatch email is provided to pharmacists as an early notification of the changes to be announced in the **March 2020** Update to the Pharmaceutical Schedule.

#### New listings

- Bortezomib inj 3.5 mg vial (Bortezomib – Dr Reddy's) (p'code 2581140) and inj 1 mg for ECP (Baxter) (p'code 2583976) – PCT only – Specialist – Special Authority
- Famotidine (Famotidine Hovid) tab 40 mg, 100 tab pack – S29 and wastage claimable (p'code 2581957)
- Gentamicin sulphate (Teligent) inj 10 mg per ml, 2 ml ampoule – S29, wastage claimable and subsidy by endorsement (p'code 2584018)
- Levomepromazine maleate (Nozinan) tab 25 mg (p'code 2581760) and 100 mg (p'code 2581779) – safety medicine; prescriber may determine dispensing frequency
- Rituximab (riximyo) inj 100 mg per 10 ml vial (p'code 2583917) and 500 mg per 50 ml vial (p'code 2583909) (Riximyo) and inj 1 mg for ECP (Baxter (Riximyo)) (p'code 2583984) – PCT only – Specialist – Special Authority
- Ropinirole (Mylan) tab 0.25 mg (p'code 2579812) and 1 mg (p'code 2579804), 100 tab pack – S29 and wastage claimable
- Triamcinolone acetonide (Kenalog) inj 40 mg per ml, 1 ml ampoule – S29 and wastage claimable (p'code 2583658)

#### Changes to restrictions, chemical names and presentations

- Bortezomib inj 3.5 mg vial (Velcade and Bortezomib – Dr Reddy's) and inj 1 mg for ECP (Baxter and Baxter (Velcade)) – amended Special Authority criteria and brand name
- Budesonide (Entocort CIR) cap 3 mg – amended Special Authority criteria
- Cilazapril with hydrochlorothiazide (Apo-Cilazapril/Hydrochlorothiazide) tab 5 mg with hydrochlorothiazide 12.5 mg – addition of subsidy by endorsement
- Etanercept (Enbrel) inj 25 mg, inj 50 mg autoinjector and prefilled syringe – amended Special Authority criteria
- Flecainide acetate (Flecainide Controlled Release Teva) cap long-acting 100 mg 200 mg – brand switch fee removed
- Fluticasone (Flixotide) aerosol inhaler, 50 mg, 125 mcg and 250 mcg per dose, 120 dose OP – amended presentation description
- Oral feed 1.5 kcal/ml (Ensure Plus and Fortisip) liquid (banana, chocolate, fruit of the forest, strawberry and vanilla) – amended subsidy by endorsement
- Rituximab (mabthera) inj 100 mg per 10 ml vial and 500 mg per 50 ml vial (Mabthera) and inj 1 mg for ECP (Baxter (Mabthera)) – amended Special Authority criteria, chemical name and brand name

A1347296

- Ruxolitinib (Jakavi) tab 5 mg, 15 mg and 20 mg – amended Special Authority criteria
- Ticagrelor (Brilinta) tab 90 mg – amended Special Authority criteria

**Increased subsidy**

Chemical	Presentation	Fully subsidised brands
Dactinomycin [actinomycin D]	Inj 0.5 mg vial	Cosmegen
	Inj 0.5 mg for ECP, 0.5 mg OP	Baxter
Gentamicin sulphate	Inj 40 mg per ml, 2 ml ampoule	Pfizer
Ornidazole	Tab 500 mg	Arrow-Ornidazole

**Decreased subsidy**

Chemical	Presentation	Fully subsidised brands	Partially subsidised brands
Bortezomib	Inj 1 mg for ECP	Baxter (Velcade)	
Fluticasone	Aerosol inhaler, 50 mcg per dose, 120 dose OP Aerosol inhaler, 250 mcg per dose, 120 dose OP	Flixotide Floair*	
Fluticasone with salmeterol	Aerosol inhaler 50 mcg with salmeterol 25 mcg, 120 dose OP Aerosol inhaler 125 mcg with salmeterol 25 mcg, 120 dose OP	Seretide RexAir*	

\* no subsidy changes for these brands for 1 March 2020.